<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768699</url>
  </required_header>
  <id_info>
    <org_study_id>TQG203-I-01</org_study_id>
    <nct_id>NCT04768699</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.</brief_title>
  <official_title>A Dose-ascending Study to Evaluate the Pharmacokinetics and Pharmacodynamics (PK/PD) of Recombinant Human Coagulation Factor VIIa for Injection in Patients With Hemophilia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of&#xD;
      recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment, based on plasma concentration of Recombinant Human Coagulation Factor VIIa.</measure>
    <time_frame>pre-dosing on Day 1 up to 24 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic assessment, based on changes of activated partial thromboplastin time (APTT).</measure>
    <time_frame>pre-dosing on Day 1 up to 24 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic assessment, based on changes of prothrombin time (PT).</measure>
    <time_frame>pre-dosing on Day 1 up to 24 hours post-dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment, based on inhibitors to Factor VIIa (FVIIa) or Factor VIII (FVIII) or Factor IX (FIX).</measure>
    <time_frame>through study completion,an average of 1year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>The presence of adverse events will be observed, reported and sufficiently handled during subjects' participation in the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia B With Inhibitor</condition>
  <arm_group>
    <arm_group_label>TQG203(30µg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TQG203(90µg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoSeven®(90µg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NovoSeven®,manufactured by Novo Nordisk Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQG203(180µg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQG203</intervention_name>
    <description>TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.</description>
    <arm_group_label>TQG203(30µg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQG203/NovoSeven®</intervention_name>
    <description>In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.</description>
    <arm_group_label>NovoSeven®(90µg/kg)</arm_group_label>
    <arm_group_label>TQG203(90µg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQG203</intervention_name>
    <description>TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.</description>
    <arm_group_label>TQG203(180µg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as congenital hemophilia A or B, and meet the following conditions: a. FⅧ&lt;1%&#xD;
             or FIX activity&lt;2%; b. FⅧ inhibitor or FⅨ inhibitor titer in the screening period&gt;5 BU&#xD;
             (Nijmegen modified Bethesda method of detection).&#xD;
&#xD;
          -  Age ≥18 and ≤75 years, male or female.&#xD;
&#xD;
          -  No other drugs for the treatment of hemophilia have been used within 48 hours (2 days)&#xD;
             before administration, including prothrombin complex and any FVII products,&#xD;
             cryoprecipitate, fresh plasma and whole blood, etc.&#xD;
&#xD;
          -  No obvious bleeding symptoms during PK medication (no active bleeding).&#xD;
&#xD;
          -  Subjects of childbearing age agree to take effective contraceptive measures throughout&#xD;
             the trial period, and continue to 28 days after the last medication.&#xD;
&#xD;
          -  Volunteer to participate in this study, sign an informed consent form, have good&#xD;
             compliance, and be able to cooperate with the experimental observation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other bleeding disease except Congenital hemophilia A or B.&#xD;
&#xD;
          -  Patients with any previous medical history or symptoms of arterial or venous&#xD;
             thromboembolic events (such as atherosclerosis, myocardial infarction, ischemic&#xD;
             stroke, transient ischemic attack, deep vein thrombosis or pulmonary hypertension&#xD;
             embolism) or disseminated intravascular coagulation (DIC).&#xD;
&#xD;
          -  Baseline and previous values of FⅦ inhibitor or rFVIIa inhibitor is positive.&#xD;
&#xD;
          -  Vitamin K deficiency.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive and cluster of differentiation 4 (CD4)&#xD;
             count ≤200/μl, the number of virus carriers ≥200 particles/μl or ≥400000 copies/ml.&#xD;
&#xD;
          -  Subjects plan to perform elective surgery during the trial period.&#xD;
&#xD;
          -  Those who are allergic to test drugs or any excipients.&#xD;
&#xD;
          -  Severe anemia and need blood transfusion.&#xD;
&#xD;
          -  Platelet count &lt;80×10^9/L.&#xD;
&#xD;
          -  Obvious liver or kidney damage: ALT or AST&gt;2.5×ULN, or total bilirubin&gt;1.5×ULN or&#xD;
             serum creatinine&gt;1.5×ULN.&#xD;
&#xD;
          -  Have a history of cardiac surgery and need anticoagulation therapy; severe heart&#xD;
             disease, including myocardial infarction, cardiac insufficiency grade 3 or above, the&#xD;
             current New York Heart Association cardiac function grade II-IV.&#xD;
&#xD;
          -  Hypertension that cannot be controlled with drug treatment: systolic blood pressure&gt;&#xD;
             150 mmHg or diastolic blood pressure&gt; 90 mmHg.&#xD;
&#xD;
          -  Participated in other clinical studies (except FVIIa, FⅧ and FⅨ trials) within one&#xD;
             month before the first medication.&#xD;
&#xD;
          -  Diagnosed with hereditary diseases such as fructose intolerance, glucose malabsorption&#xD;
             or sucrose-maltase deficiency.&#xD;
&#xD;
          -  Alcoholism, drug abuse, mental disorders, other severe acute or chronic diseases,&#xD;
             greater abnormal laboratory values, and those who are considered unsuitable by the&#xD;
             researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Zhang, Doctor</last_name>
    <phone>13502118379</phone>
    <email>zhanglei1@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Lei, Doctor</last_name>
      <phone>+86-13502118379</phone>
      <email>zhanglei1@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

